Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation

Carlos K. H. Wong,Kristy T. K. Lau,Ivan C. H. Au,Sophelia H. S. Chan,Eric H. Y. Lau,Benjamin J. Cowling,Gabriel M. Leung

DOI: https://doi.org/10.1038/s41467-024-49235-8

IF: 16.6

2024-06-09

Nature Communications

Abstract:Currently there is a lack of randomized trial data examining the use of the antiviral nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection. This target trial emulation study aims to address this gap by evaluating the use of nirmatrelvir/ritonavir in non-hospitalized paediatric patients aged 12–17 years with SARS-CoV-2 Omicron variant infection. Among paediatric patients diagnosed between 16th March 2022 and 5th February 2023, exposure was defined as outpatient nirmatrelvir/ritonavir treatment within 5 days of symptom onset or COVID-19 diagnosis. Primary outcome was 28 day all-cause mortality or all-cause hospitalization, while secondary outcomes were 28 day in-hospital disease progression, 28 day COVID-19-specific hospitalization, multisystem inflammatory syndrome in children (MIS-C), acute liver injury, acute renal failure, and acute respiratory distress syndrome. Overall, 49,378 eligible paediatric patients were included. Nirmatrelvir/ritonavir treatment was associated with reduced 28 day all-cause hospitalization (absolute risk reduction = 0.23%, 95%CI = 0.19%–0.31%; relative risk = 0.66, 95%CI = 0.56–0.71). No events of mortality, in-hospital disease progression, or adverse clinical outcomes were observed among nirmatrelvir/ritonavir users. The findings confirmed the effectiveness of nirmatrelvir/ritonavir in reducing all-cause hospitalization risk among non-hospitalized pediatric patients with SARS-CoV-2 Omicron variant infection.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the clinical effectiveness of the antiviral drug nirmatrelvir/ritonavir in non - hospitalized pediatric patients aged 12 to 17, especially after being infected with the SARS - CoV - 2 Omicron variant. Specifically, the study aims to fill the current gap in the lack of randomized trial data for patients in this age group.

### Research Background and Problem Description

1. **Background**:
- Currently, there is a lack of randomized controlled trial data on the use of nirmatrelvir/ritonavir in pediatric patients.
- This drug has been authorized for the treatment of mild - to - moderate COVID - 19 in high - risk adolescents and adults (aged 12 and above).
- However, these recommendations are mainly based on data from adult patients and were studied during the period when the Delta variant was dominant.
- During the Omicron variant epidemic, especially for unvaccinated children and adolescents, the hospitalization rate has increased.

2. **Research Questions**:
- Evaluate the effectiveness of nirmatrelvir/ritonavir in non - hospitalized pediatric patients aged 12 to 17.
- The primary outcome measure is all - cause death or all - cause hospitalization within 28 days.
- Secondary outcome measures include in - hospital disease progression within 28 days, COVID - 19 - related hospitalization within 28 days, pediatric multisystem inflammatory syndrome (MIS - C), acute liver injury, acute renal failure, and acute respiratory distress syndrome.

### Research Design and Methods

To answer the above questions, the researchers adopted the method of target trial emulation and analyzed retrospective cohort data in the Hong Kong region. The study subjects were non - hospitalized pediatric patients aged 12 to 17 who were diagnosed with SARS - CoV - 2 infection between March 16, 2022, and February 5, 2023. Exposure was defined as receiving outpatient nirmatrelvir/ritonavir treatment within 5 days after the onset of symptoms or COVID - 19 diagnosis.

Through this method, the researchers were able to better simulate the effect of a randomized controlled trial, reduce potential biases, and thus more accurately evaluate the clinical effect of nirmatrelvir/ritonavir in this specific population.

### Main Findings

The study results showed that nirmatrelvir/ritonavir treatment was significantly associated with a reduced risk of all - cause hospitalization within 28 days, with an absolute risk reduction of 0.23% (95% CI = 0.19% - 0.31%) and a relative risk of 0.66 (95% CI = 0.56 - 0.71). In addition, no deaths, in - hospital disease progression, or other adverse clinical outcomes were observed.

### Conclusions

This study indicates that in non - hospitalized pediatric patients aged 12 to 17, nirmatrelvir/ritonavir can effectively reduce the risk of all - cause hospitalization, and no obvious safety problems were found. Future research will further verify its long - term effectiveness and safety.

### Formula Representation

The main statistical results involved in the study are as follows:

- Absolute Risk Reduction (ARR): \[ \text{ARR} = 0.23\% \]
- Relative Risk (RR): \[ \text{RR} = 0.66 \]

These formulas are represented in Markdown format as follows:

```markdown
- Absolute Risk Reduction (ARR): \[ \text{ARR} = 0.23\% \]
- Relative Risk (RR): \[ \text{RR} = 0.66 \]
```

It is hoped that this information will help you understand the research purpose and main findings of this paper. If you have more questions or need further information, please feel free to let us know.